XML 30 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

License and Collaboration Agreements - Additional Information (Detail) (USD $)	3 Months Ended			3 Months Ended			3 Months Ended			12 Months Ended	3 Months Ended			3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2014 Alimera [Member]	Sep. 30, 2013 Alimera [Member]	Oct. 31, 2014 Alimera [Member] Subsequent Event [Member]	Sep. 30, 2014 Pfizer Collaboration Agreement [Member]	Sep. 30, 2013 Pfizer Collaboration Agreement [Member]	Jun. 30, 2011 Pfizer Collaboration Agreement [Member]	Jun. 30, 2011 Pfizer Collaboration Agreement [Member]	Sep. 30, 2014 Bausch and Lomb [Member]	Sep. 30, 2013 Bausch and Lomb [Member]	Jun. 30, 2014 Bausch and Lomb [Member]	Sep. 30, 2014 Enigma Therapeutics Limited [Member]	Sep. 30, 2013 Enigma Therapeutics Limited [Member]	Mar. 31, 2013 Enigma Therapeutics Limited [Member]	Sep. 30, 2014 Evaluation Agreements [Member]	Sep. 30, 2013 Evaluation Agreements [Member]
Collaborative Agreements And Contracts [Line Items]
FDA milestone payment received upon an FDA approval of ILUVIEN						$ 25,000,000
Percentage of company's share of net profits				20.00%
Pre-profitability net losses percentage				20.00%
Maximum Percentage offset of previously incurred and unapplied pre-profitability quarterly net losses				4.00%
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses				16.00%
Percentage of royalties received from sublicensee				20.00%										8.00%
Percentage of non-royalty consideration received from sublicensees				33.00%										20.00%
Loan advance received by licensee to fund FDA approval milestone				25,000,000
Collaborative research and development revenue	25,081,000	173,000		25,000,000	13,000		0	31,000						0	0		35,000	173,000
Upfront payment									2,300,000							100,000
Final report demonstrating period										90 days
License option upfront payment upon exercise										20,000,000
Estimated selling price of the deliverables for revenue recognition									6,700,000
Deferred revenue	5,600,000		5,600,000											0
Percentage of outstanding share capital owned by Pfizer	6.30%
Royalty income	226,000	424,000									226,000	424,000
Accounts receivable	25,462,000		517,000								235,000		302,000
License agreement commencement date														2012-12
Annual license maintenance fee														$ 100,000

X

- Definition

Annual license maintenance fee.

+ References

No definition available.

+ Details

Name:	psdv_AnnualLicenseMaintenanceFee
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Collaboration agreement ownership percentage in company.

+ References

No definition available.

+ Details

Name:	psdv_CollaborationAgreementOwnershipPercentageInCompany
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

X

- Details

Name:	psdv_CollaborativeAgreementsAndContractsLineItems
Namespace Prefix:	psdv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Final Report Demonstrating Proof Of Concept License Option Exercise Period

+ References

No definition available.

+ Details

Name:	psdv_FinalReportDemonstratingProofOfConceptLicenseOptionExercisePeriod
Namespace Prefix:	psdv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License Agreement Start Year Month

+ References

No definition available.

+ Details

Name:	psdv_LicenseAgreementStartYearMonth
Namespace Prefix:	psdv_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License Option Exercise Upfront Payment

+ References

No definition available.

+ Details

Name:	psdv_LicenseOptionExerciseUpfrontPayment
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Loan Advance Received To Fund Fda Approval Milestone

+ References

No definition available.

+ Details

Name:	psdv_LoanAdvanceReceivedToFundFdaApprovalMilestone
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Maximum Percentage of Quarterly Profit Sharing Offset by Previously Incurred And Unapplied Pre Profitability Net Losses

+ References

No definition available.

+ Details

Name:	psdv_MaximumPercentageOfQuarterlyProfitSharingOffsettableByPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone Payment Received Upon FDA Approval

+ References

No definition available.

+ Details

Name:	psdv_MilestonePaymentReceivedUponFdaApproval
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Non royalty consideration percentage.

+ References

No definition available.

+ Details

Name:	psdv_NonRoyaltyConsiderationPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Profit Sharing on Sale of Product Minimum Percentage After Maximum Allowable Offset of Previously Incurred And Unapplied Pre Profitability Net Losses

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductMinimumPercentageAfterMaximumAllowableOffsetOfPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Profit sharing on sale of product percentage.

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty rate percentage.

+ References

No definition available.

+ Details

Name:	psdv_RoyaltyRatePercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Share percentage of pre-profitability net losses on sale of product.

+ References

No definition available.

+ Details

Name:	psdv_SharePercentageOfPreProfitabilityNetLossesOnSaleOfProduct
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Upfront cash payment.

+ References

No definition available.

+ Details

Name:	psdv_UpfrontCashPayment
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 25

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771336&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688



Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration